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Abstract
● AIM: To compare quality of life and treatment satisfaction 
between patients who had selective laser trabeculoplasty 
(SLT) and those on medication.
● METHODS: A prospective clinical trial on 143 glaucoma 
patients that received SLT and a control group that continued 
using anti glaucoma medication was conducted. Tear 
break-up time (BUT), punctuate keratitis, need for help, 
use of artificial tears and the treatment satisfaction survey 
of intraocular pressure (IOP) were measured at baseline, 6 
and 12mo. 
● RESULTS: SLT was able to reduce the mean number of 
medications needed from 1.56±0.81 to 0.42±0.66 at six 
months and to 0.33±0.69 at one year. Punctuate keratitis 
was observed significantly less often (12.24%) after SLT 
than before (35.94%; P=0.03). Use of artificial tears and 
BUT did not change significantly after SLT (P>0.05). At 
baseline, patients in the SLT group were significantly less 
convinced of medication effectiveness (P=0.006) and com-
plained more about side effects (P=0.003). After SLT, these 
patients had significantly more confidence in their therapy 
(P<0.001), showed less side effects (P=0.006), complained 
less about changes in appearance of the eyes (P=0.003) 
and were less inconvenienced by the use of eye drops 
(P<0.001).
● CONCLUSION: SLT is able to improve treatment-related 
quality of life in glaucoma patients.
● KEYWORDS: glaucoma; laser treatment; medical treatment; 
quality of life
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INTRODUCTION
G laucoma is the second leading cause of blindness in the world[1]. Currently, the only modifiable risk factor for 
glaucoma is raised intraocular pressure (IOP). Only lowering 
of the IOP is known to delay glaucoma onset and slow down 
disease progression[2]. First line therapy of glaucoma consists 
of ocular hypotensive drugs. As in all chronic diseases, 
medical adherence is a problem[3-4]. Decades of taking local 
medications can also reduce quality of life (QoL) of glaucoma 
patients through local and systemic side effects[5-6]. 
Local side effects like irritation and a toxic effect on the anterior 
eye segment have been demonstrated for the preservative of 
anti-glaucoma medication, most often benzalkonium chloride 
(BAK)[7], as well as for the active components of glaucoma 
drops[8]. Long term use of these eye drops is associated with 
ocular surface disease[7] and induces a range of complaints and 
signs like burning, stinging, dry eye syndrome, conjunctival 
hyperemia, foreign body sensation and tearing[8-9]. These 
symptoms usually become worse in the long term and can 
result in lower adherence[4,8,10]. 
Selective laser trabeculoplasty (SLT) has proven to be a valid 
alternative to medication[11-12]. Using laser instead of medical 
therapy can get around the problems of compliance[4,9], and can 
diminish the costs[13] and side effects of anti-glaucoma drugs[14]. 
We hypothesize that treatment with SLT compared to 
continuing topical medication for controlled open angle 
glaucoma patients and patients with ocular hypertension 
(OHT), will improve patients’ treatment-related QoL.
SUBJECTS AND METHODS
Study Design and Subjects  This was a prospective clinical 
trial including 143 consecutive patients at the Glaucoma 
Consultation of Jan Palfijn Hospital, Merksem, Belgium. 
Approval of the Ethics Committee of ZNA was obtained (EC 
4313), we followed the guidelines of the Helsinki Declaration. 
Enrollment occurred from January 2014 to July 2015. Data 
were recorded at baseline, 1h, 1wk, 1, 3, 6 and 12mo post-SLT 
(Trial registration: NTR 5417, registered 23 September 2015, 
retrospectively registered.). 
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Inclusion criteria concerned primary open angle glaucoma 
(POAG) or OHT controlled with medical therapy. Patients had 
to agree to sign an informed consent form. Exclusion criteria 
were other types of glaucoma than open angle glaucoma, 
previous trabeculectomy or laser trabeculoplasty treatment. 
Patients with corneal disease that inhibited good visualization 
of the trabecular meshwork and those taking systemic steroids 
were also excluded from the study. 
Randomization of patient allocation was performed with 
a computer-generated allocation schedule using a blocked 
allocation sequence of 6 possibilities per block. Patients were 
consecutively introduced into the study; only after introduction 
of the personal patient data, the allocated group became clear 
to patient and observer. Patients were assigned to a group to 
be treated with SLT or to the control group that continued 
on topical glaucoma medication. However, we did allow 
patients who refused SLT, to enter into the control group, 
which partially biased randomization. No further masking was 
executed. In the SLT group, both eyes received SLT; the right 
eye was treated first. Only one eye of each patient was used 
for this analysis, this was chosen by a blocked randomization 
schedule.
The study was not designed to create additional IOP lowering 
effect, because IOP was already controlled with medication 
before treatment with SLT. The main goal of this study 
involved changes of ocular surface, quality of life parameters 
and treatment satisfaction. 
Baseline Examinations  At baseline a full ophthalmological 
examination of each study participant was conducted, 
including a medical history review, best corrected visual acuity 
measurement, IOP measurement using Goldmann applanation 
tonometry (mean of two measurements was taken), slit lamp 
examination of the anterior segment [conjunctival injection, 
tear break-up time (BUT), cornea, iris, lens appearance, 
gonioscopy], central corneal thickness (CCT) measurement 
(iPac Pachymeter, Reichert, Depew, USA), dilated fundus 
examination, visual field examination by computerized 
perimetry (program 24-2, Humphrey Field Analyzer 745i, 
Zeiss, Jena, Germany), optical coherence tomography (OCT) 
of the optic nerve head and recording of glaucoma medications 
and use of artificial tears. Need for help was defined as the 
complete dependency upon others to instill the glaucoma 
eye drops. All OCT scans were performed with the spectral-
domain OCT RTVue (Optovue, Fremont, USA). We used focal 
loss of volume (FLV) as determinant for the OCT[15].
IOP before treatment was calculated as the mean of three 
measurements taken on 3 different visits, each 4 to 6mo apart, 
before starting anti glaucoma medication. IOP at baseline was 
calculated as the mean of the Goldmann measurements made 
on different time points on the three last visits before laser 
treatment. 
For determination of BUT, a drop of 0.2% fluorescein solution 
was applied to the inferior fornix, and the participant was 
asked to close his/her eyes. Using the blue light of the slit 
lamp, the time in seconds between eyelid opening and the 
appearance of initial defects in the tear film was measured. The 
same examiner performed all examinations. 
Laser Technique  A frequency doubled, Q-switched Nd:YAG 
laser was used, emitting a wavelength of 532 nm, coupled 
to a slit lamp delivery system (Selecta Duet laser, Lumenis, 
Dreieich, Germany). We used single pulses with pulse duration 
of 3ns and spot size of 400 µm. The laser energy was initially 
set at 0.9 mJ and a single laser pulse was delivered at the 12 
o’clock position. If a cavitation bubble appeared, the laser 
energy was reduced by 0.1 mJ increments until minimal 
bubble formation was observed. Treatment was then continued 
at this energy level[16]. If no cavitation bubble was observed, 
the pulse energy was increased by steps of 0.1 mJ until bubble 
formation. Immediately before the laser procedure a drop of 
pilocarpine 1% and apraclonidine 0.5% were instilled into the 
treated eye. After the laser treatment, no anti-inflammatory 
drops were administered. 
Postoperative Management  Patients were examined 1h, 
1wk, 1, 3, 6, 12 and 18mo after SLT. They received a clinical 
examination as part of their routine glaucoma care at 6 and 
12mo, comparable to the examination at baseline. After SLT, 
anti-glaucoma drops were continued until IOP was more 
than 2 mm Hg below target pressure, at which point they 
were stopped one by one. A fixed combination of drugs was 
considered as a combination of two medications; the first step 
entailed a switch to a single medication. The second drug was 
stopped if possible, after respecting a minimal wash out period 
of three months. The number of applications daily was not 
changed during the study; a medication was continued at the 
normal frequency or stopped. 
Quality of Life  We used the Treatment Satisfaction Survey 
for Intraocular Pressure (TSS-IOP) to assess patients’ 
satisfaction with their anti-glaucoma treatment. The TSS-IOP 
questionnaire is a patient reported outcome measure designed 
to assess patients’ perception of the treatment used to lower 
their IOP[17]. The validation study was presented by Atkinson 
et al[18] in 2003, a clinical application of the test was published 
in 2006[11]. We translated the questions in Flemish, the patients’ 
language. A non-exclusive right to use the TSS-IOP was 
granted to our study group by Pfizer in December 2013 for the 
duration of the trial protocol.
TSS-IOP contains four questions about perceived effectiveness 
of treatment (Questions 1-2, 16-17) in which patients are asked 
how satisfied they are about their treatment and how convinced 
they are that the treatment will maintain eye pressure within the 
normal range. The questions concerning unintended treatment 
effects (Questions 3-5) inquire about burning or stinging of 
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the eyes, feelings of grittiness or sandiness or the presence 
of crusts around the eyes. Three questions examine whether 
the treatment induces redness of the eye or other changes in 
appearance (Questions 7-9, 18). Convenience of use of the 
medication (Questions 10-12) inquires about the number of 
times per day a treatment has to be applied, at which time and 
if this can be easily remembered. Ease of administration of the 
drops (Questions 13-15) concerns the difficulty of getting the 
drops into the eye and whether only one or more drops have 
been applied. 
All of these questions are assessed by 5- to 7-level answers 
ranging from e.g. “very sure” to “very unsure”. Higher scores 
are indicative of greater satisfaction. The questionnaire was 
filled out at baseline, after 6 and 12mo. Patients were given 
time to do so in the waiting room, so as not to feel pressured 
by the physician to answer the questions in a certain direction. 
Individual scores were computed by adding the scale values 
of the answers within an item, and transforming the resulting 
value into a score between 0 and 10 018. 
Statistical Analysis  An independent-samples t-test was 
performed to compare baseline differences between the SLT 
and the control group for continuous variables (i.e. age, IOP at 
baseline with medication, vision, cup-disc ratio, CCT, visual 
field mean deficit, OCT FLV, IOP before treatment, number 
of medications at baseline). A χ2 test was used to compare 
baseline differences in sex and type of glaucoma (POAG or 
OHT). A second independent-samples t-test was executed 
to investigate the difference in evolution of mean IOP for 
both groups at all time points. The same analysis was run 
to investigate the time-evolution in tear BUT. A χ2 test was 
performed to examine the number of medications and need 
for help. The t-test was also performed to evaluate the BUT, 
whereas χ2 test was used to investigate the occurrence of 
punctuate keratitis and the use of artificial tears. Analysis of the 
TSS questionnaire was performed using a generalized linear 
regression-test. Results of statistical analysis with P<0.05 were 
considered to be significant. 
RESULTS
Population  Demographic and baseline characteristics are 
shown in Table 1. No significant differences were present 
between the SLT and the control group for most baseline 
characteristics. At baseline, more patients were taking 
prostaglandin analogues in the SLT compared to the control 
group. Studies by Lai et al[19] and Singh et al[20] however 
showed that pre-laser glaucoma medication, more specifically 
prostaglandins, does not influence the outcome of SLT.
Laser Technique  All patients received a 360° treatment of the 
trabecular meshwork. We used a mean number of 102.03±8.39 
non-overlapping spots with a mean energy of 1.10±0.30 mJ. 
The same experienced surgeon (De Keyser M) applied all 
treatments. 
Table 1 Baseline characteristics of the population                                                                                                           n (%) 
Demographics SLT group (n=64) Control group (n=61) P
Age (a) 68.59±12.84 72.07±11.79 0.17
Sex (M/F) 33 (51.56)/31 (48.44) 30 (49.18)/31 (50.82) 0.47
Risk factors1 1.52±0.96 1.64±1.32 0.13
Glaucoma parameters
IOP before medication (mm Hg) 23.21±5.28 22.92±4.50 0.98
IOP at baseline with medication (mm Hg) 13.66±3.35 12.47±3.31 0.07
POAG/OHT 52 (81.25)/12 (18.75) 42 (68.85)/19 (31.15) 0.11
BCVA 0.85±0.22 0.81±0.22 0.28
CCT (µm) 545.66±44.25 552.20 ±40.46 0.24
Cup disc ratio 0.83±0.82 0.76±0.62 0.57
Visual field MD 5.07±6.04 5.23±6.59 1.0
Visual field PSD 4.43±3.31 4.59±3.72 0.84
OCT FLV 4.34±4.52 4.88±4.67 0.52
Medication at start
Total number 1.56±0.81 1.39±0.67 0.57
Prostaglandinanalogs 59 (92.19) 48 (78.69) 0.03
Betablocker 26 (40.63) 29 (47.54) 0.44
Carboanhydrase inhibitor 10 (15.63) 6 (9.84) 0.34
Alphamimetics 5 (7.81) 2 (3.28) 0.27
IOP: Intraocular pressure; BCVA: Best corrected visual acuity; POAG: Primary open angle glaucoma; OHT: Ocular 
hypertension; CCT: Central corneal thickness; MD: Mean deviation; PSD: Pattern standard deviation; OCT: Optical 
coherence tomography; FLV: Focal loss of volume in %. 1Risk factors: myopia, hypertension, diabetes, migraine, vascular 
problems, family history of glaucoma. 
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Evolution of Intraocular Pressure and Medication  Totally 
72 patients were appointed to the SLT group, 64 of them 
completed a minimum six months of follow up, 49 were 
followed for one year. The control group contained 71 patients; 
61 patients completed the minimal six months follow up 
schedule, 30 of them also completed the one-year follow up. 
No severe complications were recorded; data collection was 
stopped for practical reasons, resulting in limited follow up 
time. 
IOP did not change significantly in both SLT and control groups, 
as was expected in this population of patients controlled under 
medication (Table 2). In the SLT group, the mean number of 
medication needed lowered from 1.56 at baseline to 0.42 at 
six months and 0.33 after 12mo. The difference compared to 
the control group was significant at 6 (P<0.001) and 12mo 
(P<0.001). 
In the control group at baseline, 42 patients (68.85%) were 
taking one anti glaucoma medication; 15 patients (24.59%) 
were on two medications, 3 (4.92%) took three different 
medications and one (1.64%) took four medications. In the 
SLT group the number of patients on respectively one, two, 
three and four medicationsat baseline was 39 (60.94%), 16 
(25.00%), 7 (10.94%) and 2 (3.13%). After one year, 38 
(77.55%) of the patients in the SLT group no longer needed 
any medication to maintain their IOP. Seven patients (14.29%) 
were using one drop, 3 (6.12%) still needed two different drops 
and one patient (2.04%) needed three medications.
“Need for help” to instill the eye drops was comparable 
between the SLT and the control group at baseline, but patients 
in the SLT group needed significantly less help 6 (P=0.002) 
and 12mo (P=0.01) after SLT (Table 2). 
Anterior Segment Condition  Mean BUT was below normal 
but comparable for SLT and control group (6.23s vs 6.13s) at 
all time points, as shown in Table 3. At baseline, 35.94% and 
31.15% of patients showed punctuate keratitis in the SLT and 
control group respectively. Six months after SLT, there was a 
trend towards less punctuate keratitis (14.06%) (P=0.14) in the 
SLT group; after 12mo, the difference in punctuate keratitis 
(12.24%) compared to the control group became significant 
(P=0.03). Totally 35.94% of the patients in the SLT group and 
24.59% of the control group at baseline used artificial tears. 
The use of artificial tears did not change significantly in both 
groups during follow up (Table 3). 
Quality of Life/Treatment Satisfaction Survey for Intraocular 
Pressure Questionnaire  At baseline, there was a significant 
difference between the SLT and the control group for all items 
except ease of administration. Patients that were in some way 
bothered by their therapy, seemed to be motivated easier to 
have an SLT performed. Therefore, we further analyzed the 
evolution of each item within the groups (Tables 4, 5).
All items of the questionnaire (perceived effectiveness of the 
treatment, side effects, eye appearance changes, convenience 
of use of therapy, ease of administration of eye drops) 
remained the same in the control group that continued using 
the same medication. However, all of the examined items 
improved significantly one year after use of SLT (P<0.001). 
Table 5 TSS evolution
Parameters Groups Baseline 12mo P
Perceived effectiveness SLT 65.79±11.76 77.99±14.07 <0.001
Control 70.78±11.96 68.33±14.22 0.39
Side effects SLT 67.51±13.07 75.00±16.18 0.006
Control 74.04±12.06 73.19±16.44 0.76
Eye appearance SLT 74.93±17.84 83.93±14.38 0.003
Control 81.69±13.05 80.00±17.14 0.57
Convenience of use SLT 67.56±18.35 83.38 ±24.59 < 0.001
Control 75.25±13.71 68.10±23.73 0.07
Ease of administration SLT 56.17±21.20 82.06±26.94 <0.001
Control 57.64±26.36 53.68±28.47 0.51
TSS: Treatment satisfaction survey.
Table 4 TSS comparison between SLT and control group at 
baseline
Parameters SLT group Control group P
Perceived effectiveness 65.79±11.76 70.78±11.96 0.006
Side effects 67.51±13.07 74.04±12.06 0.003
Appearance 74.93±17.84 81.69±13.05 0.01
Convenience of use 67.56±18.35 75.25±13.71 0.01
Administration 56.17±21.20 57.64±26.36 0.67
TSS: Treatment satisfaction survey.
Table 3 Anterior segment condition
Parameters Time SLT group Control group P
BUT (s) Baseline 6.23±2.89 6.13±2.95 1
6mo 6.61±2.67 5.97±2.44 0.21
12mo 6.90±2.87 6.27±2.70 0.57
Punctuate keratitis (%) Baseline 23 (35.94) 19 (31.15) 0.57
6mo 9 (14.06) 15 (24.59) 0.14
12mo 6 (12.24) 9 (30.00) 0.03
Artificial tear use (%) Baseline 23 (35.94) 15 (24.59) 0.18
6mo 20 (31.25) 21 (34.43) 0.85
12mo 18 (36.73) 13 (43.33) 0.63
BUT: Tear break up time.
Table 2 Evolution of IOP/medication use/need for help        n (%)
Parameters Time SLT group Control group P
IOP (mm Hg) Baseline 13.61±3.37 12.53±3.36 0.07
6mo 11.58±3.39 10.49±4.39 0.14
12mo 11.06±2.90 10.93±3.53 0.58
No. of medications Baseline 1.56±0.81 1.39±0.67 0.57
6mo 0.42±0.66 1.38±0.69 <0.001
12mo 0.33±0.69 1.33±0.76 <0.001
Needed help (%) Baseline 12 (18.75) 18 (29.51) 0.16
6mo 6 (9.38) 19 (31.15) 0.002
12mo 6 (12.24) 11 (36.67) 0.01
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DISCUSSION
The medical treatment of glaucoma has a number of side 
effects, is expensive and often inconvenient to instill. It is 
therefore not surprising that glaucoma frequently has a large 
impact on a patients’ QoL[4-6]. The burden of this treatment, 
including cost[13], inconvenience[7-8] tolerability[9] and QoL[4] are 
factors that the doctor and patient should discuss because they 
can lead to poor or noncompliance, followed by progression of 
disease[10].
As in any chronic disease, noncompliance with drug therapy 
of glaucoma medication poses a therapeutic problem[3]. The 
addition of a second or third medication or therapeutic is 
correlated with a significant decrease in adherence[3]. Using eye 
drops more times a day, leads to a higher trend to disregard the 
treatment[17]. With effective laser trabeculoplasty, eliminating 
or reducing the need for glaucoma medications[13] may 
minimize the impact of compliance. 
Lowering of Medication  Compared to the control group 
on medication, SLT lowered the number of anti glaucoma 
medications significantly (P<0.001) and when still medication 
was needed after laser treatment, SLT simplified the treatment 
schedules. Similar findings have been reported by several 
studies[12,21-24]. 
In our study, use of SLT produced a mean drop of 1.23 
medications. This is in agreement with the study from Lai 
et al[19] who reported a mean of 0.99-1.08 less medications 
needed after SLT. Amean of 0.7 less medications was reported 
by Bovell et al[25], five years after using SLT. Francis et al[26] 
recorded a very large mean drop of medication of 2.0 drops 
per person after six months. However, they started with an 
average of 2.79 medications taken at baseline, while we started 
with a mean of 1.56 medications per patient. Francis et al[26] 
showed that 63% of their patients were able to discontinue 
all eye drops. In our study, 77.55% of the patients that were 
treated with SLT no longer needed medication after one year 
of follow up. The patients remaining on medication had a 
simplified treatment schedule. The QoL study of Day et al[17] 
demonstrated that glaucoma patients are more satisfied about 
their treatment when they only need to instill one medication 
instead of using several. This was in part due to the decreased 
ocular irritation associated with dosing less medication and 
partly related to greater convenience of use from instilling 
fewer dosages per day[8,17]. 
A very large cohort study by Nordstrom et al[4] demonstrated 
that physicians traditionally overestimate the adherence of their 
patients to their local glaucoma treatment since nearly half of 
the patients discontinued the initially prescribed drop therapy 
completely within six months. Using SLT can make us at least 
sure of actually treating the patient. 
Need for Help  Part of patients’ QoL is also their independence. 
In a large cross sectional study on QoL in glaucoma patients, 
Odberg et al[5] found that 11% of glaucoma patients were 
dependent upon help from relatives or others to instill their 
medication. In this context, Sleath et al[27] showed that 
unmarried patients had significantly more problems than 
married patients in managing their glaucoma and confessed 
more often to be less than 100% adherent. We recorded 12 
patients in the SLT group (20%) and 18 in the control group 
(30%) at baseline that needed help from others to install their 
drops. This changed little in the control group, but the amount 
lowered significantly in the SLT group at 6 and at 12mo to 
10% and 12% (P=0.01), suggesting enhanced independence. 
Anterior Segment Condition  As reported in several studies, 
ocular surface disease and reduced BUT are very common 
in glaucoma patients[7-9,14,28]. The severity of the reported 
symptoms is positively correlated to the number of IOP 
lowering medications used[9,14,28]. Leung et al[28] recorded 
a reduced BUT in 78% of glaucoma patients on local 
medication. In our study, BUT was reduced in 72.80% of 
patients, we found no difference in BUT between the SLT and 
the control group at any time point. 
At baseline, punctuate keratitis was recorded in 31.15% 
to 35.94% of the patients. There was a trend towards less 
punctuate keratitis in the SLT group (14.06%) after six months, 
which became statistically significant after 12mo (12.24%; 
P=0.03). The incidence of punctuate keratitis at baseline 
was higher in our groups than in a report by Pisella et al[9], 
which showed a prevalence of 19% of superficial punctuate 
keratitis among patients using glaucoma medication. Leung 
et al[28] recorded 22% of their patients showing corneal and 
conjunctival lissamine green staining. Our progressive decrease 
may be explained by additional decrease of medication, or 
by the fact that epithelial recovery takes some time. A large 
segment of our glaucoma patients were taking artificial tears 
at baseline: 35.94% in the SLT group and 24.59% in the 
control group. At the six months follow up this number was 
significantly lower in the SLT group (31.25%) while it was 
raised in the control group (34.43%). Being part of a study 
possibly drew attention to side effects (scratching, redness, 
sandy feeling), leading to more artificial tears use in the control 
group after 6 and 12mo. 
In a study of Costa et al[29], more glaucoma patients (53%) 
used artificial tears compared to their age-matched controls 
(18%) without glaucoma therapy. Pisella et al[9] registered 
use of artificial tears in 19% of their glaucoma patients. Our 
findings seem to lie in between those of Costa et al[29] and the 
ones from Pisella et al[9], confirming more need for artificial 
tears in patients on anti glaucoma treatment.
Quality of Life  
Perceived effectiveness  Satisfaction or dissatisfaction with 
medication predicts patients’ continuance of their treatment, the 
correct use of medication and compliance with the medication 
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regimens[18]. In our study, patients that agreed to have an SLT 
done were less sure of the effectiveness of the medication they 
were taking (P=0.006); complained more about its side effects 
(P=0.003) and were bothered more by the inconvenience of 
using eye drops (P=0.01). They had difficulties putting in the 
drops and using only one drop at a time, but this did not differ 
from the control group (P=0.67). After the laser treatment, all 
these parameters scored significantly better in the SLT group. 
Patients believed more in the effectiveness of treatment, had 
less burning and stinging of the eyes, the eye appearance 
improved and remaining medication was easier to remember 
and to apply.
Similar findings were reported by a treatment related study 
by Odberg et al[5], who took patients on glaucoma medication 
and examined their QoL. Half of their patients treated with 
laser or surgery evaluated their situation as improved after 
these operations. Possible explanations were the relief by 
doctor and patient related to a lowering of the IOP or to a 
lesser need of medication. Odberg et al[5] stated that it is likely 
that a satisfactory regulation of the IOP without use of topical 
therapy will give patients a better QoL.
Nordmann et al[6], who did a large cross-sectional survey 
studying the link between patient-reported side effects of anti-
glaucoma medication and vision-related QoL, reported that 
poor subjective treatment satisfaction was related to poor 
vision related QoL, which in turn could be connected to less 
compliance. Since compliance is of major importance to get 
the full potential protective effect against visual field defect, 
tolerance of and satisfaction with treatment are a critical 
issue[17].
Side effects  Pisella et al[9] questioned a group of 4107 patients 
on anti glaucoma medication; 61% of patients reported some 
kind of irritation. The prevalence of signs and symptoms was 
dose-dependent and increased with the number of preserved 
eyedrops usedby the patient. Odberg et al[5] noted complaints 
about side effects in 47% of their glaucoma patients; most 
common were itching (24%) and pain (10%). Nordmann et al[6] 
reported 62.4% of their glaucoma patients complained of 
at least one local side effect. Presence of local side effects 
correlated to poor treatment satisfaction andto additional visits 
to the ophthalmologist. 
In a study of Schwartz et al[30] hyperemia was noted by the 
physician in 19.5%-31.5% of the patients on prostaglandin 
analogues for glaucoma; it was a common reason for 
medication change and responsible for additional therapeutic 
costs. In our study the questionnaire recorded a significant 
improvement in side effects and complaints about eye 
appearance after SLT.
Ease and convenience of use  Multiple medications and multiple 
daily administrations can be an inconvenience and, for a 
subset of patients with dexterity problems, present significant 
difficulties to its use. The costs and side effects (discoloration 
of eye lids) associated with wastage of product by missing 
the eye can be a substantial concern for patients[17]. Use 
of SLT minimized the inconveniences associated with the 
administration of medications (P<0.001).
Limitations of This Study  Patients who had been allocated to 
the SLT treatment by the randomization program, but refused 
this, were allowed to serve as control patients. This interfered 
with proper randomization. However, in our opinion this does 
not deter from the fact that all complaints improved after SLT. 
Secondly, the TSS-IOP questions were translated taking into 
account translation, back-translation and cultural adaptation. 
No further specific methodology was used. TSS-IOP includes 
questions referring to the use of medication and ease of 
administration of eye drops. This is less applicable after SLT 
since this simplifies treatment schedules. However, problems 
with use and administration of medication can result in loss of 
compliance, so it should be taken into account when deciding 
to use SLT or not. Using a vision specific QoL questionnaire 
would have been another option, but vision does generally not 
change in glaucoma patients within the restrictions of a one to 
two year study period[31]. 
Clinicians tend to over-estimate compliance[3,32] and 
underestimate the impact on QoL of glaucoma medication[5-7]. 
SLT can significantly lower the burden of treatment for 
glaucoma patients with respect to QoL, as well as convenience 
and tolerability of the treatment.
In conclusion, SLT significantly lowers the amount of anti 
glaucoma medication needed and improves treatment-related 
QoL. Patients show less dependence upon help of others to 
instill drops, have less punctuate keratitis and less subjective 
side effects. They are convinced of the effectiveness of their 
treatment and have fewer problems applying any remaining 
drops. Maybe SLT should become first-line treatment instead 
of medication in the therapy of glaucoma.
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